Anti-CD30L Antibody Therapy for Refractory IBD Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are few targeted therapies available for autoimmune disorders such as inflammatory bowel disease (IBD), particularly for patients who are non-responsive or lose response to existing treatments, and current therapies have variable efficacy and side effects.

Innovation Solution

Development of antibodies that bind to CD30 ligand (CD30L) to inhibit its interaction with CD30, thereby reducing immune activation and inflammatory cytokine expression, including interleukin-6 and interleukin-8, which are key players in inflammatory and autoimmune diseases like Crohn's disease and ulcerative colitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing IBD therapies are used, then treatment is provided, but variable efficacy and side effects occur

Engineering Contradiction:

Improvetherapy efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the molecular target parameter from general immune system components to specifically CD30L, a marker expressed on activated T cells and certain malignancies. This parameter change enables more precise targeting of the immune response pathway involved in IBD, improving efficacy while reducing off-target side effects compared to conventional non-specific immunosuppressants

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses anti-CD30L antibodies as intermediary molecules that mediate the therapeutic effect by binding to CD30L on activated T cells. This intermediary approach allows the therapy to specifically modulate the CD30L-CD30 interaction pathway, achieving variable efficacy control with reduced harmful effects compared to direct non-specific immunosuppression

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If non-responsive or lost response patients receive existing therapies, then treatment is provided, but therapeutic benefit is insufficient

Engineering Contradiction:

Improveresponse rateVSAvoidtherapeutic benefit

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent identifies and targets CD30L as a specific parameter that is dysregulated in IBD pathogenesis. By changing the therapeutic parameter to target CD30L specifically, the therapy can activate alternative pathways for achieving response in non-responsive patients, improving both response rate and therapeutic benefit through mechanism-based precision

Inventive Principle:

Principle #35Parameter changes

3Reliability

If targeted therapy is developed, then specificity is improved, but development complexity increases

Engineering Contradiction:

Improvetherapy specificityVSAvoidtherapy development

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs anti-CD30L antibodies as intermediary therapeutic agents that leverage existing antibody drug development frameworks. This intermediary approach allows targeted specificity to be achieved through standardized antibody engineering platforms, reducing the overall development complexity compared to creating entirely new classes of targeted therapeutics from scratch

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250340660A1Anti-CD30l antibodies, formulations therefor, and uses thereof

Publication Date: 2025.11.06 DR FALK PHARMA GMBH

AI summary

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).